Pegasus Biologics' OrthADAPT(TM) Bioimplant Receives CE Mark.IRVINE, Calif. -- Pegasus Biologics, Inc., a privately held developer of unique bioimplants for soft tissue repair, and wound care for diabetic ulcers, announced today that it has received CE Mark certification for the commercial sale of its OrthADAPT[TM] Bioimplant. The OrthADAPT[TM] Bioimplant is a highly organized Type I collagen scaffold used for the repair, reinforcement and augmentation AUGMENTATION, old English law. The name of a court erected by Henry VIII., which was invested with the power of determining suits and controversies relating to monasteries and abbey lands. of soft tissues including tendons and ligaments. The Bioimplant is processed using Pegasus Biologics' proprietary crosslinking and sterilization sterilization Any surgical procedure intended to end fertility permanently (see contraception). Such operations remove or interrupt the anatomical pathways through which the cells involved in fertilization travel (see reproductive system). technologies that make it resistant to premature enzyme degradation and biocompatible biocompatible /bio·com·pat·i·ble/ (-kom-pat´i-b'l) being harmonious with life; not having toxic or injurious effects on biological function. to allow remodeling remodeling /re·mod·el·ing/ (re-mod´el-ing) reorganization or renovation of an old structure. bone remodeling . "Receiving CE Mark approval is a major milestone for our Company. European surgeons will have a new option for the treatment of soft tissue repairs which their U.S. counterparts have been utilizing for the past year and a half," said Pegasus Biologics President and Founder, France Dixon Helfer. "These surgeons are looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. ways to augment their patients' repairs; the damaged tissue which oftentimes is weakened, or of poor quality. The OrthADAPT[TM] Bioimplant will provide them with a safe and effective solution for treating their patients. Our products and technologies are being enthusiastically embraced by surgical communities here in the U.S. and we anticipate a similar response abroad." Al Weinstein, Executive Vice President of Sales added, "This is a significant milestone for our Company as we can now expand our market presence throughout the European Community European Community: see European Union. European Community (EC) Organization formed in 1967 with the merger of the European Economic Community, European Coal and Steel Community, and European Atomic Energy Community. and in many other countries accepting the CE Mark. The OrthADAPT[TM] Bioimplant has applications in thousands of orthopedic procedures, including ligaments and tendons, sports medicine sports medicine, branch of medicine concerned with physical fitness and with the treatment and prevention of injuries and other disorders related to sports. Knee, leg, back, and shoulder injuries; stiffness and pain in joints; tendinitis; "tennis elbow"; and , as well as foot and ankle soft tissue procedures. With our competitive advantages and core platform technologies, we are well positioned to capture a significant share of the OUS business as we gear up our international distribution network." Pamela Misajon, Vice President of Regulatory and Clinical Affairs stated, "The CE Mark is an indication that our company has met essential health, safety and performance protection requirements detailed in the European Medical Device Directive 93/42/EEC. The CE Mark allows our products to gain access to the EU market, assuring patients of the safety and efficacy of the designated products." Pegasus Biologics reports that the OrthADAPT[TM] Bioimplant has been used in the treatment of more than 2,500 patients since its formal launch last year. About Pegasus Biologics, Inc. Pegasus Biologics, Inc. (Irvine, CA) is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. focused on the research, development and commercialization of next generation biologics utilizing the Company's unique and patented technologies. Additional information on the Company can be found at www.pegasusbio.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion